Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans

Journal of the Neurological Sciences

Volumn 164, Issue 2, 1999, Pages 148-152

  Rovaris, Marco ^a   Mastronardo, Giovanna ^a   Prandini, Francesca ^b   Bastianello, Stefano ^c   Comi, Giancarlo ^d   Filippi, Massimo ^a  

^a Department of Cardiology   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Gadolinium enhancement; Lesion evolution; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DEMYELINATION; DOSIMETRY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; BRAIN; COHORT STUDIES; CONTRAST MEDIA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GADOLINIUM DTPA; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; TIME FACTORS;

EID: 0033121184     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00054-4     Document Type: Article

References (23)

1. Kermode A.G., Thompson A.J., Tofts P.S., MacManus D.G., Kendall B.E., Kingsley D.P.E., Moseley I.F., Rudge P., McDonald W.I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 113:1990;1477-1489.
2. McDonald W.I., Miller D.H., Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol. 18:1992;319-334.
3. Miller D.H., Barkhof F., Nauta J.J.P. Gadolinium enhancement increased the sensitivity of MRI in detecting disease activity in MS. Brain. 116:1993;1077-1094.
4. Stone L.A., Albert P.S., Smith M.E., DeCarli C., Armstrong M.R., McFarlin D.E., Frank J.A., McFarland H.F. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology. 45:1995;1808-1814.
5. van Waesberghe J.H.T.M., van Walderveen M.A.A., Castelijns J.A., Scheltens P., Lycklama à Nijeholt G.J., Polman C.H., Barkhof F. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization MR. Am J Neuroradiol. 19:1998;675-683.
6. 1-weighted MR and quantitative magnetization transfer. Am J Neuroradiol. 16:1995;1473-1479.
7. van Walderveen M.A.A., Kamphorst W., Scheltens P., van Waesberghe J.H.T.M., Ravid R., Valk J., Polman Ch., Barkhof F. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology. 50:1998;1282-1288.
8. Filippi M., Miller D.H. MRI in the differential diagnosis and monitoring the treatment of multiple sclerosis. Curr Opin Neurol. 9:1996;176-186.
9. Silver N.C., Good C.D., Barker G.J., MacManus D.G., Thompson A.J., Moseley I.F., McDonald W.I., Miller D.H. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 120:1997;1149-1161.
10. Filippi M., Yousry T., Campi A., Kandziora C., Colombo B., Voltz R., Martinelli V., Spuler S., Bressi S., Scotti G., Comi G. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology. 46:1996;379-384.
11. Filippi M., Rovaris M., Capra R., Gasperini C., Yousry T.A., Sormani M.P., Prandini F., Horsfield M.A., Martinelli V., Bastianello S., Kuhne I., Pozzilli C., Comi G. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain. 121:1998;2011-2020.
12. Lublin F.D., Reingold S.C. The National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
13. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
14. Miller D.H., Barkhof F., Berry I., Kappos L., Scotti G., Thompson A.J. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry. 54:1991;683-688.
15. Katz D., Taubenberger J.K., Cannella B., McFarlin D.E., Raine C.S., McFarland H.F. Correlation between magnetic resonance imaging findings and lesion development in multiple sclerosis. Ann Neurol. 34:1993;661-669.
16. Filippi M., Rocca M.A., Rizzo G., Horsfield M.A., Rovaris M., Minicucci L., Colombo B., Comi G. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology. 50:1998;1289-1293.
17. Filippi M., Rovaris M., Capra R., Gasperini C., Martinelli V., Sormani M.P., Bastianello S., Comi G. Serial standard- and triple-dose MRI to monitor the effect of interferon β-1a on multiple sclerosis activity (Abstract). Neurology. 50:(Suppl 4):1998;A323.
18. Tofts P.S., Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts. Magn Reson Med. 17:1991;357-367.
19. Lai M., Hodgson T., Gawne-Cain M., Webb S., MacManus D.G., McDonald W.I., Thompson A.J., Miller D.H. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry. 60:1996;339-341.
20. Bruck W., Bitsch A., Kolenda H., Bruck Y., Stiefel M., Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 42:1997;783-793.
21. 1-weighted) spin-echo images. Neurology. 45:1995;1684-1690.
22. Truyen L., van Waesberghe J.H.T.M., van Walderveen M.A.A., van Oosten B.W., Polman C.H., Hommes O.R., Adèr H.J.A., Barkhof F. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 47:1997;1469-1476.
23. Lai H.M., Davie C.A., Gass A., Barker G.J., Webb S., Tofts P.S., Thompson A.J., McDonald W.I., Miller D.H. Serial magnetisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis. J Neurol. 244:1997;308-311.